



# New Challenges in Drug Allergy: the Resurgence of Excipients

Mónica Venturini Díaz, MD, PhD<sup>1, \*</sup>

Irene Vidal Oribe, MD<sup>1</sup>

Diana D'Elia Torrence, MD<sup>1</sup>

Pilar Hernández Alfonso, MD<sup>1</sup>

Eladia Alarcón Gallardo, MD, PhD<sup>2</sup>

## Address

<sup>\*,1</sup>Allergy Department, Hospital Universitario San Pedro, CARPA San Millán, Obispo Lepe Sn., 26004 Logroño, La Rioja, Spain  
Email: mventurini@riojasalud.es

<sup>2</sup>Allergy Department, Hospital de Calahorra, Calahorra, La Rioja, Spain

© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

This article is part of the Topical Collection on *Drug Allergy*.

**Keywords** Excipient · Allergy · Drug · Vaccine · Hypersensitivity · Diagnosis

## Abstract

*Purpose of Review* Allergy to excipients is a cause of multidrug allergy and if it is not taken into account, it can lead to unexpected severe reactions. If an excipient allergy is suspected, an accurate examination followed by algorithms is very important for a correct diagnosis and to give patients detailed information in order to avoid future reactions.

*Recent Findings* In recent times, due to allergy COVID vaccine reactions, interest in excipients as polyethylene glycol derivatives (PEGs) has increased as a possible cause of drug and vaccine hypersensitivity. In addition to PEGs many other excipients as gelatin, alpha-gal, protamine, benzalkonium chloride, and benzyl alcohol have been described as a cause of allergy to drugs and vaccines. For most excipients, the dilutions used for skin testing (ST) are not standardized and proper algorithms to reach a diagnosis are not available.

*Summary* The purpose of this article is to review the excipients that may produce immediate hypersensitivity drugs and vaccine reactions and update diagnostic procedures to reach an accurate diagnosis. We highlight the in vivo and in vitro diagnostic tests used in published reports and detail the dilution used for each excipient to perform ST in order to confirm this vital pathology and to prevent new reactions.

## Introduction

The European Medicines Agency (EMA) "Guideline on excipients in the dossier for application for marketing authorization of a medicinal product" [1] and the Current Good Manufacturing Practices [2] define an excipient or inactive ingredient as the constituents of the pharmaceutical form other than the active ingredient. It should be noted that in recent times, due to the SARS-CoV2 pandemic and allergic reactions described to the COVID-19 vaccines, interest in excipients has increased as a possible cause of drugs and vaccine hypersensitivity [3]. For both drugs and vaccines, these are rare reactions; however, for vaccines, they are the primary cause of immediate hypersensitivity reactions (IHRs) [4••].

We should suspect this problem when a patient reports unrelated multiple drug reactions. In this case, an accurate examination followed by algorithms is very

important for correct diagnosis and to give patients detailed information in order to avoid future reactions. However, the diagnostic procedure for allergy to excipients is not properly protocolized. The purpose of this article is to review the excipients that may produce immediate hypersensitivity drug and vaccine reactions and update diagnostic procedures to assess the involvement of each excipient in this type of reactions. We focus on reactions suggestive of being due to a type I hypersensitivity mechanism and other reactions such as delayed ones are not included in this review.

Systematic review, using the electronic searching in engine Pubmed/Medline until March 2021, was performed. We draw up an alphabetical list of excipients detailing the publications found about each of them. We highlighted the in vitro and in vivo tests used to confirm the diagnosis.

## Aluminum

A case of anaphylaxis after a tetanus vaccination that includes aluminum as an excipient (Tetavax®) was reported in the literature. The patient previously described urticaria and angioedema after use of a large number of non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, antihistamine preparations, methylprednisolone and colchicum. Most of these drugs were proven by provocation tests with good tolerance. A Finn Chamber® with pure elemental aluminum was placed on to the inner side of the forearm. An immediate urticarial lesion under the Finn chamber® that expanding up the entire arm was observed [5].

## Benzyl alcohol

Turvey et al. described a patient with repeated anaphylactic reactions following vitamin B12 injections containing benzyl alcohol and no reaction to intranasal cyanocobalamin gel that does not contain benzyl alcohol. Skin prick-tests (SPT) with cyanocobalamin brand (1 mg/ml) and benzyl alcohol (0,9%) were negative but intradermal testing (IDT) with cyanocobalamin brand (0.01 mg/ml) and benzyl alcohol (0.009%) were positive [6].

Another case of vitamin B12 allergy due to benzyl alcohol sensitization has been previously reported with positive IDT (0.9%) [7].

One patient treated with benzyl alcohol-preserved cytarabine, vincristine, and heparin solutions developed an IHR on three separate occasions. The reaction was not seen on subsequent treatment with a non-preserved diluent. Hypersensitivity to benzyl alcohol was confirmed by IDT (0.9%) [8].

## Benzalkonium chloride

Some cases of IHR to benzalkonium chloride have been reported with salbutamol nebulizer solution (Ventolin®) [9] eye drops [10] and xylometazolin hydrochlorid descongastant nose drops (Otriven®) [11] containing benzalkonium chloride.

SPT were carried out with three different concentrations of benzalkonium chloride (0.01% solution, 0.1% solution, 0.5% solution, each dissolved in H<sub>2</sub>O). Mild reaction at 0.1% and very strong reaction at 0.5% was obtained [10].

ST with benzalkonium chloride should be done with caution because anaphylactic shock following an IDT with 1:10 salbutamol nebulizer solution containing benzalkonium chloride is reported [9].

## Carboxymethylcellulose (CMC)

Several case reports of anaphylaxis due to CMC have been reported. The drugs involved in this type of severe reaction range from intramuscular [12–14], intra-articular [15–17] or intradermal [18] triamcinolone-containing injections to barium sulfate suspension [19] and eye lubricant solution [20]. A case of contact urticaria due to hydrocolloid dressings containing CMC has also been described in the literature [21].

The diagnosis of CMC hypersensitivity was reached by means of SPT and IDT with different dilutions; Li et al. used preservative free Carmellose eye drops 1% (10 mg/ml) (Moorfields Pharmaceuticals, London, UK) undiluted for SPT and 1:10 dilution for IDT [12]. Al Haditi et al. proposed IDT with CMD diluted at 0.001 and 0.01 mg/ml [16] and our working group are using Carmelosa Qualigen 5 mg/ml (Neuraxpharm, Spain) undiluted for SPT and diluted 1:100 and 1:1000 for IDT (0.05 and 0.005 mg/ml) [14] with good results.

In some reports, in vitro test as dot blot [20], basophil activation test (BAT) [13], enzyme-linked immunoassay (ELISA) [22], and in vitro histamine release [19] with CMC and with the suspected drugs, verified that reactions were induced by this excipient.

## Carrageenan

Tarlo et al. reported a case of anaphylaxis during barium enema due to carrageenan allergy that showed positive SPT with 0.4% wt/vol sodium carrageenan and specific IgE antibodies (RAST) [23].

## Cremophor

Cremophor EL (polyethoxylated castor oil, Kollipor EL) is prepared by reacting ethylene oxide with castor oil in a ratio of 35:1, so it is considered a PEG, PEG castor oil [24••]. Cremophor RH40 (macroglycerol hydroxystearate, Kolliphor RH40) instead is obtained by hydrogenated castor oil reacted with ethylene oxide at a molar ratio of 1:40 (hence the synonym PEG-40 hydrogenated castor oil) [25•]. Similarities among Cremophor EL, Cremophor RH40, and polyoxyethylated oleic glycerides may be taken into consideration, suggesting different patterns of cross-reactivity [25•].

Anaphylactoid reactions induced by CrEL have been described. Manifestations vary from IHRs, postulating an IgE-mediated mechanism according to the positive of ST performed, to complement activation via the alternative pathway, leading into inflammatory mediators release [26]. Some authors suggested IgG antibodies involvement according to Parusnitz-Kustner test and BAT [27], and other studies suggested direct histamine release by basophils or mast cells [27, 28].

IHRs have been described mostly induced by taxanes, and in most cases attributed to the vehicle used for administering them (Cremophor EL® and Tween 80, in Paclitaxel and Docetaxel respectively). The absence of Cremophor in some new formulations (nanoparticle albumin-bound paclitaxel, Nab-paclitaxel) led to a lower incidence of this toxicity. Besides taxanes, IHRs to cyclosporine for intravenous infusion have been reported [27], and less frequently to the oral presentation/formulation [27, 29] (due to polyoxyl-5-oleate, the solvent of the oral solution).

The lack of standardization regarding diagnostic tests makes the demonstration of the underlying immunological mechanism challenging. In most of the cases reported, ST were not performed or exclusively SPT (Table 1).

## Ethylenediaminetetraacetic acid (EDTA)

We only found a case in the literature of allergy to EDTA [33]. It is a patient who had a history of generalized urticaria after administration of a radiocontrast medium (RCM) (Isovue®) who developed anaphylaxis with subcutaneous injection of lignocaine (Lignospan Special®). IDT to calcium disodium EDTA 0.3 mg/ml was strongly positive and subcutaneous challenge with 0.1 ml and 0.5 ml resulted positive. IDT with undiluted RCM were positive in several RCM except for Iomeron 300®, the only RCM that does not contain EDTA. BAT was also positive with EDTA.

**Table 1 Concentration of skin tests performed in previous studies/cases reported with Cremophor and drugs that contain it**

<b>Drug</b>	<b>Prick test dilutions (mg/ml)</b>	<b>Intradermal test dilutions (mg/ml)</b>
Pacitaxel	1/10 (6 mg/ml) [30] 1/1 (undiluted, 6 mg/ml) [25•]	1/1000 (0,006) [30] 1/100 (0,06) [30] 1/10 (0,6) [30]
Cremophor EL	Undiluted (concentration not detailed) [31]	NP
PEG 35 castor oil (Cremophor EL, product number: 238470)	1/1 (undiluted, 527 mg/ml) [32•]	NP
* PEG 3350 Lax-A-Day®	* PEG-35 diluted in etanol 50% to reach a concentration of 527 mg/ml. The mixture was vortexed until the solution was clear	
* PEG 3350 PegLyte®		
Cyclosporine (Neoral-Sandimmun® IV, 250 mg/5 ml, excipient Cremophor EL 650 mg/ml)	1/1 (undiluted) [25•]	1/10000 (0,065 mg/ml Cremophor EL) [25•]
Vitamin A Nepalim® (retinol palmitate 100,000 IU/2 ml, excipient Cremophor RH40 concentration not specified)	1/1 (undiluted) [25•]	1/10000 [25•]
NP not performed		

## FD&C yellow 6 (sunset yellow)

Taneja et al. reported a patient who developed generalized maculopapular rash after intake FD&C yellow 6 containing warfarina, ciprofloxacin and nitrofurantoin formulations with good tolerance to the same active ingredients without FD&C yellow 6 [34]. Diagnosis was made by clinical history [34].

## Food proteins

### Cow's milk protein (CMP)

#### *Casein*

Preparations of iron protein succinylate in drinkable vials: Ferplex<sup>®</sup>, Ferroc<sup>®</sup>, and Lactoferrin<sup>®</sup> contain high amounts of casein [35]. A case of anaphylaxis after the intake of Ferplex<sup>®</sup> has been reported in a child previously diagnosed with cow's milk allergy. The authors confirmed the diagnosis by SPT with undiluted Ferplex<sup>®</sup> and specific IgE determination by enzyme allergosorbent test (EAST) [36]. They also demonstrated the presence of casein in iron proteinsuccinylate by EAST inhibition.

Some lots of the Diphtheria, Tetanus, and Pertussis vaccines (DTaP) that are processed in a broth derived from casein, can be contaminated by this protein. Kattan et al. identified 8 patients with severe milk allergy who had an anaphylaxis with booster doses of DTaP [37]. The authors identified casein in 8 lots of the vaccines (range 8 to 18 ng/mL). They concluded that residual casein in the vaccines might result in reactions for some highly sensitive patients with milk allergy.

---

#### *Alpha lactalbumin (ALA) and bovine serum albumin (BSA)*

It is reported a 10-month-old male patient with cow's milk allergy who had an anaphylactic reaction after receiving a single-component of measles vaccine (M-VAC<sup>®</sup>; Serum Institute of India, Hadapsar, Pune, India) with lactalbumin hydrolysate. The authors did not performed ST with the vaccine to confirm the diagnosis but at 12 months old, the child received the MMR (Priorix<sup>®</sup>; GlaxoSmithKline, Canada) vaccine, without any reaction [38].

Four children who had history of severe IgE-mediated allergy to cow's milk, suffered IHRs after vaccination with the oral polio vaccine (OPV, Trivalent vaccine Polioral<sup>®</sup>; Sclavo, Siena, Italy). Prick to prick with Sabin vaccine resulted positive. Levels of Sabin vaccine-specific IgE (ELISA) were increased and the authors confirmed the presence of ALA in the OPV by means indirect and competitive ELISA method [39].

IgE to BSA was seen in the majority of patients with cow's milk or beef allergy that have had hypersensitivity reactions to vaccines (measles, Japanese

encephalitis, rabies primary chick embryo, pentavalent, diphtheria and tetanus, and adult diphtheria and tetanus) in Sri Lanka. It was concluded that BSA might be the allergen responsible for the vaccine-associated allergic reactions [40].

Martín Muñoz et al. [41] studied the presence of egg and cow's milk hidden allergens in 11 probiotics commercially available in Spain. SPT with the probiotics (20 mg/ml) were performed in children allergic to cow's milk, to hen's white egg, and controls. ELISA, SDS-PAGE immunoblotting, and inhibition studies were performed to demonstrate the presence of egg and CMP. CMP as BSA and ALA were detected in 10/11 probiotics, three over 2.5 mg/kg. Hen's egg white proteins were detected in 3/11 probiotics, only one had more than 2.5 mg/kg.

## Lactose

Several cases of IHRs induced by Sol-Medrol® 40 mg (methylprednisolone sodium succinate) have been reported in cow's milk allergy patients [42–45]. There are 4 different doses of methylprednisolone sodium succinate, and lactose is found only in the 40 mg preparation (25 mg of lactose per vial). The diagnosis was confirmed by positive SPT and/or ID with Sol-Medrol® 40 mg used respectively at the concentration of 40 mg/ml and 0.4 y 4 mg/ml [44, 45] being negative for Sol-Medrol® 125 mg [43].

The presence of CMP in ten different batches of Sol-Medrol® 40 mg was assessed by SDS-PAGE and immunoblotting methods [43] or ELISA assay [44]. A quantitative analysis of BLG in Sol-Medrol® 40 mg and 1 g of lactose found 112.5 ng of  $\beta$ -lactoglobulin per Sol-Medrol® 40 mg vial and 1.35  $\mu$ g of BLG per gram of lactose [42].

Lactose was found to be the culprit of anaphylactic reactions after the inhalation of Inavir® (Laninamivir Octanoate Hydrate) to treat flu infection in an asthmatic patient [46]. SPT and BAT resulted positive for Inavir® inhaler powder and lactose but negative for Laninamivir. The contamination of milk proteins in lactose excipient was demonstrated by Western blotting using specific monoclonal antibody and patient's sera.

Another cases of refractory asthma exacerbation [47] and anaphylaxis [48] have been elicited by inhaling dry powder containing fluticasone/salmeterol (Advair Diskus, GlaxoSmithKline, Research Triangle Park, NC) in patients with milk allergy due to lactose contaminated by milk proteins.

## Egg proteins

### *Lysozyme*

IHRs with different drugs containing lysozyme have been reported: nystatin and tetracycline vaginal suppository [49], mucolytic Leftose® [50], nasal decongestant containing neomycin, dexamethasone and chlorphenamine

[51], nasal decongestant Narlism® [52] and Lizipaina® tablets (with bacitracin and papain) [53].

The diagnosis was performed by serum specific IgE (CAP System, Pharmacia, Uppsala, Sweden) against lysozyme and SPT with commercialized available extracts of egg white and lysozyme. In some cases, prick-to-prick with the drug containing lysozyme resulted positive [50, 52].

---

### *Ovalbumin (OVA)*

The amount of OVA in residual medium of influenza vaccines is less than 0.4 mcg per 0.5 ml dose and <3 ng per 0.5 ml dose in the case of rabies vaccine, while higher amounts of egg protein have been found in yellow fever vaccine (<4.42 mcg/ml) [54••].

Although anaphylaxis after influenza immunization is a theoretical risk, different studies suggest that most individuals with egg allergy can be safely vaccinated with a single dose of the influenza vaccine, even those with severe egg allergy [55–59]. The authors do not recommend the use of ST because all of the patients tolerated the vaccine [55] neither IDT that were found to be irritative [54••]. They concluded that the vaccine can be administered without supervision by an allergist [59].

Other similar studies are needed to investigate the tolerance of with rabies and yellow fever vaccines. Actually, the vaccination protocol with yellow fever vaccine proved to be safe for patients with a history of egg allergy [60, 61•]. Consists in perform SPT using undiluted vaccine and if negative, IDT with the vaccine diluted 1:100 in normal saline. If ST resulted negative, the patient can be vaccinated under medical supervision using 1 simple dose. If the ST are positive and the benefits to receive the vaccine outweigh the risks, the dose of vaccine should administered in graded doses under observation [54••, 60, 61•].

## **Gelatin and $\alpha$ -Gal**

---

The oligosaccharide galactose- $\alpha$ -1,3-galactose ( $\alpha$ -Gal) is the cause of IHRs after exposure to some drugs that contain the molecule as part of its active ingredient such as the monoclonal antibody cetuximab [62], the Crotalidae polyvalent immune Fab antivenom [63•] and bovine-derived gelatine colloids [64]. This type of reactions has also been described with drugs and vaccines that contain gelatin as an excipient such as fenticonazole vaginal capsule [65] and varicella zoster and measles/mumps/rubella (MMR) vaccines [66, 67].

Gelatin is a bovine or porcine protein generated by partial hydrolysis and treatment of collagen and is used as a stabilizer in drugs and attenuated viral-containing vaccines such as Japanese encephalitis virus and MMR.

Gelatin can induce both vaccine [68] and drug allergy [69•]. There have been reports of anaphylaxis caused by gelatin capsules with include common oral cold medications (Advil Liqui-Gels®, Stona IB Gel®), and anesthetic suppositories (Chloral hydrate suppository®) [69•].

Although  $\alpha$ -Gal has been recognized as part of the gelatin molecules responsible for some of vaccine's allergy [66, 67], a case of zoster vaccine anaphylaxis has been reported in a patient who had IgE to gelatin but not to  $\alpha$ -Gal [70].

Sakaguchi et al. identified the alpha 2 chain of type I collagen as the causative agent in children who showed anaphylaxis to bovine gelatin containing live virus vaccines [68].

For gelatin allergy diagnosis, bovine gelatin-derived colloids undiluted as Haemacel® and Gelofusine®, with 35 and 40 mg/ml gelatin respectively, have been used for SPT and IDT [64]. We also can perform a determination of IgE antibodies to porcine and bovine gelatin and bovine thyroglobulin  $\alpha$ -gal using serum specific IgE test commercially available. In  $\alpha$ -gal allergic patients ST with gelatin-derived colloids showed strong correlation with anti- $\alpha$ -Gal IgE measurements [64]. Cetuximab (Erbitux, Merck S.L.) can also be used to perform ST and BAT with high sensitivity and specificity [71]. The concentrations proposed are 5 mg/mL for SPT and 5  $\mu$ g/mL for IDT [71].

SPT using the undiluted vaccine an IDT with the vaccine diluted 1:100 in normal saline seem to be non irritative and support the vaccine allergy diagnosis [54••].

## Hexylene glycol

---

A case of contact urticaria, angioedema, and dyspnea following the application of a topical mometasone furoate cream (Elocom®), caused by hexylene glycol, has been reported. A positive reaction was present to pure hexylene glycol at 1 and 10% concentrations by prick and rub tests. No cross-reactivity to propyleneglycol or PEG was detected [72].

## Hydroxypropyl methylcellulose

---

A case of anaphylaxis to hydroxypropyl methylcellulose (HPMC) on 2 different occasions during cataract surgery was reported due to Ocucoat® and Xylocaine gel®. In the case of Xylocaine gel®, HPMC was an excipient but in Ocucoat® was the active ingredient. SPT were positive for Ocucoat gel® (with 2% HPMC) [73].

## Macrogols

---

Macrogols, also named PEGs, constitute a large family of hydrophilic polymers derived from ethylene oxide [4••, 67, 74] that includes PEGs of varying molecular weights (MW) and some other related molecules, such polysorbates (PS) [4••, 67].

They are commonly used as excipients in many different products like pharmaceuticals and cosmetic but also as active ingredients in laxatives and bowel preparations and as part of the PEGylation process of several drugs [4••, 74, 75••, 76•]. Due to their structural similarity, cross-sensitization between PEGs and PS has been described [67, 77–79], even though its clinical relevance has not been clearly assessed [4••, 74, 75••, 80•, 81••].

Interest in macrogols has notably increased lately due to their role in the reported reactions with COVID-19 vaccines. Nevertheless, they are so widely distributed that they have been related to IHRs of diverse severity for years.

PEG 8000 and 6000 were found to be the culprit agents in anaphylactic reactions with an ultrasound gel [82], and with a povidone-iodine gel [77] and PEGs with MW between 3000 and 6000 in IHRs after oral intake of nonrelated drugs [78, 79, 83•, 84]. Anaphylaxis due to PEG 3350 and 4000 with laxative agents during bowel preparation [83•, 84, 85], after injection of corticosteroids [86] and ultrasound contrast agent [87] have also been described. At times, patients reported previous IHRs to products containing macrogols [77–79, 84, 85].

As known, mRNA vaccines against SARS-CoV-2 Moderna® and Pfizer® BioNTech contain PEG 2000. ST with PEGs in the diagnosis of COVID-19 vaccines allergy is controversial. While some reports demonstrate the involvement of this excipient in IgE-mediated reactions with mRNA COVID-19 vaccines [87, 88], a recent published meta-analysis underlines the poor sensitivity of ST and suggests against routinely performing them [81••].

PS 20 and PS 80 are common excipients in biological drugs and they have been involved in IHRs after the administration of several monoclonal antibodies [89, 90]. PS 80 has also been related with IgE-mediated reactions with corticosteroids [91], etoposide [92], quadrivalent human papillomavirus vaccine [93], erythropoietin, and darbepoietin [94].

One of the most challenging points in the diagnosis of macrogol allergy is the lack of agreement on how to perform ST and, undoubtedly, there is a need to create standardized protocols with validated concentrations.

In literature, in those cases where diagnosis was reached by ST with macrogols, authors use different concentrations [75••].

We have a wide experience in testing PS 80 at concentrations proposed by Palacios et al.—SPT at 0.4 mg/ml and IDTs at 0.004 mg/ml and 0.04 mg/ml—and we can assure that they are non-irritating.

According to the drug allergy committee of the Spanish Society of Allergology and Immunology (SEAIC) and following the diagnostic approach recommended by Sellaturay et al. and Palacios et al. we suggest a testing protocol with macrogols (Table 2). We have found those concentrations non-irritating. Nonetheless, further studies are needed to assess their sensitivity.

In certain cases, it may be advisable to perform ST with higher MW PEGs, as they can be diagnostic when lower MW PEGs test negative [74, 76•, 80•, 83•]. Systemic reactions with IDTs with PEGs have been described. Hence, it is essential to perform stepwise SPT before carrying out IDT [76•, 80•, 83•].

**Table 2** Proposed concentrations for skin testing with macrogols [91, 95•]

	PEG 1500 (Roxall)	PEG 2000	PEG 3350 (Movicol®)	PEG 4000 (Casenlax®)	PS 80
Prick-test	1 mg/ml	1 mg/ml	2.5 mg/ml	2.5 mg/ml	0.4 mg/ml
	10 mg/ml	10 mg/ml	25 mg/ml	25 mg/ml	
	100 mg/ml	100 mg/ml			
Intradermal test	0.01 mg/ml	0.0001 mg/ml	0.00025 mg/ml	0.00025 mg/ml	0.004 mg/ml
		0.001 mg/ml	0.0025 mg/ml	0.0025 mg/ml	0.04 mg/ml

## Mannitol

IHR to intravenous mannitol are usually attributed to the hyperosmolar properties, being able to trigger a non-specific mast-cells or basophils degranulation produced by non-immunologic mechanism [96, 97].

There are some reports that show that mannitol can induce a true IgE-mediated reaction: two cases of allergy to mannitol in intravenous paracetamol (Perfalgan®) [98], a case with granular effervescent paracetamol (Tachipirina®) [99] and another one with the intake of a chewable tablet of cisapride (Cisapid MPS®) [100]. Mannitol SPT resulted positive with 1% w/v (10 mg/ml) concentration [100] in some reports. Other researchers obtained negative SPT with mannitol 20% but IDT to manitol diluted at 1:1000, 1:100 and 1:10 gave a positive response [98, 99].

## Metacresol

Wheeler et al. documented a case of an allergic reaction to the metacresol component of different insulins [101]. The patient suffered pain, localized erythema with skin breakdown occurring within 5 min after the injection that evolved into multiple healing abrasions at the different puncture points. Subcutaneous testing resulted positive with all available insulin and metacresol was the only excipient common to all. Since it was not available commercially for testing, subcutaneous testing was performed with Lilly™ "saline" penfills that containing metacresol as the only significant ingredient eliciting an identical positive reaction.

## Poloxamer 238

A clinical case of anaphylaxis due to poloxamer 238 has been described in literature during a radiological examination with intravenous injection of a marker with Tc99m (Nanocoll®) that contains this excipient. SPT and

IDT (1:1000) with poloxamer 238 were positive and negative in 5 controls. A histamine release test was also positive [102]. As poloxamers are block copolymers of PEG and polypropylene glycol, cross-reactivity between poloxamers and macrogols could potentially occur.

## Povidone (polyvinylpyrrolidone PVP).

Anaphylaxis due to povidone iodine have been reported after intravenous administration of paracetamol that contains this excipient [101]. Another cases of anaphylactic reaction after oral intake of flubendazole suspension (Fluvermal®) [103], acetaminophen-containing tablets (Doregrippin®) [104], intra-articular paramethasone acetate [105], prednisolone oral solution (Estilsona®) [106], and loteprednol eye drop [107] have also been reported.

PVP allergy diagnosis was confirmed in some cases by a positive SPT with 5% povidone iodine (aqueous solution) diluted 1:100 with normal saline (0.5 mg/ml) [108] or betadine solution without dilution (100 mg/ml or 75 mg/ml) [106, 107]. Other authors demonstrated specific IgE antibodies against PVP using a dot blot technique [104].

## Protamine

Several cases of severe IHRs after subcutaneous injections of neutral protamine Hagedorn (NPH) have been described [109, 110, 111]. Some patients have also past history of anaphylactic shock after intravenous administration of protamine sulfate used for heparin reversal [109, 110].

Diagnosis was reached by means of positive serum specific IgE and ST for protamine and protamine containing insulin and negative to protamine free insulin. Currently, we have available the comercial technique of InmunoCAP® for protamine and insulin specific IgE determination.

Blanco et al. proposed to carry out SPT with different insulins at a concentration of 40 UI/ml and with protamine sulfate at 10 mg/ml. They also perform ID with serial tenfold dilutions of insulins and protamine starting with a 1:100,000 dilution, reaching a maximum of 0.4 UI/ml for insulins and 0.1 mg/ml for protamine [112].

## Tromethamine or trometamol

We only have found a case of an anaphylactic reaction to Trometamol on the literature [113••] induced by the parenteral administration of gadoteridol (Prohance®).

SPT with undiluted gadolinium contrast agents and IDT in the range 1:1000, 1:100, and 1:10 dilutions were performed. SPT and IDT with

trometamol diluted to same concentration as that contained in the index gadolinium contrast agents were also performed. They resulted negative to gadoterate meglumine (Dotarem®), the only one that does not contain Trometamol and positive at 1:100 concentration, with gadoteridol (Prohance®) and gadobutrol (Gadovist®), and at 1:1000 to trometamol.

With the recent appearance of COVID 19 vaccines, and being Trometamol one of the excipients, it is also suspected to be the responsible for some of the vaccine reactions described [114••].

## Zinc

---

A patient developed an IHR after the administration of NPH, detemir and rapid insulin with positive SPT to zinc chloride 5 µg/ml (10, 20 and 40 fold diluted). He tolerated zinc-free glulisine insulin [115].

Another case of IHR with Monotard® (porcine monocomponent insulin), Monotard HM® (human semisynthetic monocomponent insulin) was described. IDT were negative to bovine, porcine, and human insulin, but strongly positive to diluting medium for Monotard and to zinc acetate (dilutions not detailed). The patient was completely free from allergic manifestations after switching to Actrapid HM® (human semisynthetic monocomponent insulin) [116].

We have also found two reports of cutaneous generalized allergy due to the use of porcine insulin (Monotard®) and also human Protaphane® and Humulin NPH®. IDT were negative for insulin but strongly positive for diluting medium for Monotard, zinc acetate and protamine (dilutions not detailed) [117, 118].

## Conclusion

---

Excipients in drug and vaccine formulations represent a true puzzle for allergists. At a first sight, the active pharmaceutical molecule is usually considered the responsible agent for a IHR, but all vaccine and drug components should be considered as potential triggers of an allergic reaction. For this reason, a careful investigation is required for the correct identification of the culprit agent.

We also would like to highlight the significance of clear labelling of all ingredients including excipients in pharmaceutical preparations and reiterate the importance and value of an allergological work-up in order to provide planning advice to avoid future reactions.

For some excipients such as gelatin, alpha-gal, and food-derived excipients, we have in vivo and in vitro diagnostic tests with high sensitivity and specificity, but for most excipients, we must continue working to improve diagnostic procedures.

## Declarations

---

### Conflict of Interest

Mónica Venturini Díaz declares that she no competing interests. Vidal Irene declares that she no competing interests. D'Elia Diana declares that she no competing interests. Alarcón Eladia declares that she no competing interests.

### Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

## References and Recommended Reading

---

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. European Medicines Agency. Guideline On Excipients In The Dossier For Application For Marketing Authorisation Of A Medicinal Product. Available online: [https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-excipients-dossier-application-marketing-authorisation-medicinal-product-revision-2\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-excipients-dossier-application-marketing-authorisation-medicinal-product-revision-2_en.pdf). Accessed on 7 Aug 2019.
2. U.S. Food and Drug Administration CFR - Code of Federal Regulations Title 21. Available online: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=210.3>. Accessed on 1 Aug 2019.
3. Ortega NR, Audicana MT, de la Hoz B, Valero A. The century of mRNA vaccines: COVID-19 vaccines and allergy. *J Investig Allergol Clin Immunol*. 2021;31(1):89–91. <https://doi.org/10.18176/jiaci.0665>.
4. •• Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone CA Jr. Hidden dangers: recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. *J Allergy Clin Immunol Pract*. 2021;9(8):2968–2982. <https://doi.org/10.1016/j.jaip.2021.03.002>.  
This is an excellent review about immediate and delayed hypersensitivity reactions to excipients.
5. Kutlu A, Ucar R, Aydin E, Arslan S, Caliskaner AZ. Could aluminum be a new hidden allergen in type 1 hypersensitivity reactions when used as a drug additive? *Postepy Dermatol Alergol*. 2016;33(3):243–5. <https://doi.org/10.5114/ada.2016.60620>.
6. Turvey SE, Cronin B, Arnold AD, Twarog FJ, Dioun AF. Adverse reactions to vitamin B12 injections due to benzyl alcohol sensitivity: successful treatment with intranasal cyanocobalamin. *Allergy*. 2004;59(9):1023–4. <https://doi.org/10.1111/j.1398-9995.2004.00507.x>.
7. Grant JA, Bilodeau PA, Guernsey BC, Gardner FH. Unsuspected benzyl alcohol hypersensitivity. *N Engl J Med*. 1982;306(2):108. <https://doi.org/10.1056/NEJM198201143060215>.
8. Wilson JP, Solimando DA Jr, Edwards MS. Parenteral benzyl alcohol-induced hypersensitivity reaction. *Drug Intell Clin Pharm*. 1986;20(9):689–91. <https://doi.org/10.1177/106002808602000912>.
9. Kim SH, Ahn Y. Anaphylaxis caused by benzalkonium in a nebulizer solution. *J Korean Med Sci*. 2004;19(2):289–90. <https://doi.org/10.3346/jkms.2004.19.2.289>.
10. Mezger E, Wendler O, Mayr S, Bozzato A. Anaphylactic reaction following administration of nose drops containing benzalkonium chloride. *Head Face Med*. 2012;18(8):29. <https://doi.org/10.1186/1746-160X-8-29>.
11. Anderson D, Faltay B, Haller NA. Anaphylaxis with use of eye-drops containing benzalkonium chloride preservative. *Clin Exp Optom*. 2009;92(5):444–6. <https://doi.org/10.1111/j.1444-0938.2009.00395.x>.
12. Li PH, Wagner A, Thomas I, Watts TJ, Rutkowski R, Rutkowski K. Steroid allergy: clinical features and the importance of excipient testing in a diagnostic algorithm. *J Allergy Clin Immunol Pract*. 2018;6(5):1655–61. <https://doi.org/10.1016/j.jaip.2018.01.007>.
13. Niwa Y, Hayama K, Tagui T, Ito-Watanabe M, Endo T, Fujita H, et al. Case of anaphylaxis due to carmellose sodium. *J Dermatol*. 2020;47(1):e15–7. <https://doi.org/10.1111/1346-8138.15107>.

14. Venturini M, Lobera T, del Pozo MD, González I, Blasco A. Immediate hypersensitivity to corticosteroids. *J Investig Allergol Clin Immunol.* 2006;16(1):51–6.
  15. Montoro J, Valero A, Elices A, Rubira N, Serra-Baldrich E, Amat P, et al. Anaphylactic shock after intra-articular injection of carboxymethylcellulose. *Allergol Immunopathol (Madr).* 2000;28(6):332–3.
  16. Al Hadithy A, van Maaren M, Vermes A. Anaphylactic reactions following Kenacort-A® injection: carboxymethylcellulose is involved once again. *Contact Dermatitis.* 2011;64(3):179–80. <https://doi.org/10.1111/j.1600-0536.2010.01850.x>.
  17. Townsend K, Laffan J, Hayman G. Carboxymethylcellulose excipient allergy: a case report. *J Med Case Rep.* 2021;15(1):565. <https://doi.org/10.1186/s13256-021-03180-y>.
  18. Laing ME, Fallis B, Murphy GM. Anaphylactic reaction to intralesional corticosteroid injection. *Contact Dermatitis.* 2007;57(2):132–3. <https://doi.org/10.1111/j.1600-0536.2007.01092.x>.
  19. Muroi N, Nishibori M, Fujii T, Yamagata M, Hosoi S, Nakaya N, et al. Anaphylaxis from the carboxymethylcellulose component of barium sulfate suspension. *N Engl J Med.* 1997;337(18):1275–7. <https://doi.org/10.1056/NEJM199710303371804>.
  20. Carbonell A, Miralles JC, Escudero AI, Martínez A, Pineda F, Aldana D. Urticaria-angioedema due to carboxymethylcellulose eye drops. *J Investig Allergol Clin Immunol.* 2012;22(4):288–9.
  21. Johnsson M, Fiskerstrand EJ. Contact urticaria syndrome due to carboxymethylcellulose in a hydrocolloid dressing. *Contact Dermatitis.* 1999;41(6):344–5. <https://doi.org/10.1111/j.1600-0536.1999.tb06187.x>.
  22. Muroi N, Mori S, Ono S, Takahashi HK, Fujii T, Hosoi S, et al. Allergy to carboxymethylcellulose. *Allergy.* 2002;57(12):1212–3. <https://doi.org/10.1034/j.1398-9995.2002.238934.x>.
  23. Tarlo SM, Dolovich J, Listgarten C. Anaphylaxis to carrageenan: a pseudo-latex allergy. *J Allergy Clin Immunol.* 1995;95(5 Pt 1):933–6. [https://doi.org/10.1016/s0091-6749\(95\)70091-9](https://doi.org/10.1016/s0091-6749(95)70091-9).
  - 24.●●Barbaud A, Garvey LH, Arcolaci A, Brockow K, Mori F, Mayorga C, et al. Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper. *Allergy.* 2022. <https://doi.org/10.1111/all.15241>.
- Position paper about the recommendations for the management of patients with allergy related to anti-COVID-19 vaccines.
- 25.● Renier R, Breynaert C, Dens A, Tuyls S, Schrijvers R. Allergic reactions to polyethoxylated castor oil derivatives: a guide to decipher confusing names on pharmaceutical labels. *J Allergy Clin Immunol Pract.* 2020; 8(3):1136–1138. <https://doi.org/10.1016/j.jaip.2019.09.030>.
- Overview of the chemical structures, synonyms, and a list of the drugs containing polyethoxylated castor oil derivatives.
26. Weiszhar Z, Czucz J, Révész C, Rosivall L, Szebeni J, Rozsnay Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. *Eur J Pharm Sci.* 2012;45(4):492–8. <https://doi.org/10.1016/j.ejps.2011.09.016>.
  27. Volcheck GW, Van Dellen RG. Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review. *Ann Allergy Asthma Immunol.* 1998;80(2):159–63. [https://doi.org/10.1016/S1081-1206\(10\)62949-3](https://doi.org/10.1016/S1081-1206(10)62949-3).
  28. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. *J Natl Cancer Inst.* 1998;90(4):300–6. <https://doi.org/10.1093/jnci/90.4.300>.
  29. Moeinian M, Sotoude H, Mohebbi Z, Asadollahi-Amin A, Mozafari R. Well-tolerated oral cyclosporine in a case of hypersensitivity to parenteral cyclosporine in postalloge-neic bone marrow transplantation. *Indian J Pharmacol.* 2018;50(2):94–6. [https://doi.org/10.4103/ijp.IJP\\_99\\_18](https://doi.org/10.4103/ijp.IJP_99_18).
  30. Pagani M, Bavbek S, Alvarez-Cuesta E, Berna Dursun A, Bonadonna P, Castells M, et al. Hypersensitivity reactions to chemotherapy: an EAACI Position Paper. *Allergy.* 2022;77(2):388–403. <https://doi.org/10.1111/all.15113>.
  31. Kim NY, Kim JY, Kim JW, Kim JH, Kim HI, Yune S, et al. The hidden culprit: a case of repeated anaphylaxis to cremophor. *Allergy Asthma Immunol Res.* 2016;8(2):174–7. <https://doi.org/10.4168/aaair.2016.8.2.174>.
  - 32.● Picard M, Drolet J, Masse M, Filion CA, ALMuhizi F, Fein M, et al. Safety of COVID-19 vaccination in patients with polyethylene glycol allergy: a case series. *J Allergy Clin Immunol Pract.* 2022;10(2):620–625. <https://doi.org/10.1016/j.jaip.2021.11.021>.
- This paper describe a case serie of 12 PEG-allergic patients that tolerated COVID-19 vaccines.
33. Russo PA, Banovic T, Wiese MD, Whyte AF, Smith WB. Systemic allergy to EDTA in local anesthetic and radiocontrast media. *J Allergy Clin Immunol Pract.* 2014;2(2):225–9. <https://doi.org/10.1016/j.jaip.2013.12.001>.
  34. Taneja V, Taneja I, Mihali AB, Pawar R. Excipient hypersensitivity masquerading as multidrug allergy. *Am J Med.* 2021;134(8):e447–8. <https://doi.org/10.1016/j.amjmed.2021.02.015>.
  35. Audicana MT, Barasona MJ, Corominas M, De Barrio M, García MC, García JC, et al. Drug Allergy Committee of the Spanish Society of; Allergology and Clinical Immunology (Sociedad Española de Alergología e; Inmunología Clínica, SEAIC). Potential hypersensitivity due to the food or food additive content of medicinal products in Spain. *J Investig Allergol Clin Immunol.* 2011;21(7):496–506.
  36. Larramendi CH, Marco FM, García-Abujeta JL, Mateo M, de la Vega A, Sempere JM. Acute allergic reaction to an iron compound in a milk-allergic patient. *Pediatr Allergy Immunol.* 2006;17(3):230–3. <https://doi.org/10.1111/j.1399-3038.2005.00373.x>.
  37. Kattan JD, Konstantinou GN, Cox AL, Nowak-Węgrzyn A, Gimenez G, Sampson HA, et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow's milk allergy. *J Allergy Clin Immunol.* 2011;128(1):215–8. <https://doi.org/10.1016/j.jaci.2011.04.046>.
  38. Sipahi S, Ozceker D, Gokcay G, Guler N, Tamay Z. A case of anaphylaxis to measles vaccination in an infant with cow's milk allergy. *Pediatr Allergy Immunol Pulmonol.* 2019;32(3):135–8. <https://doi.org/10.1089/ped.2019.0993>.

39. Parisi CA, Smaldini PL, Gervasoni ME, Maspero JF, Docena GH. Hypersensitivity reactions to the Sabin vaccine in children with cow's milk allergy. *Clin Exp Allergy*. 2013;43(2):249–54. <https://doi.org/10.1111/cea.12059>.
40. de Silva R, Dasanayake WMDK, Wickramasinha GD, Karunatilake C, Weerasinghe N, Gunasekera P, et al. Sensitization to bovine serum albumin as a possible cause of allergic reactions to vaccines. *Vaccine*. 2017;35(11):1494–500. <https://doi.org/10.1016/j.vaccine.2017.02.009>.
41. Martín-Muñoz ME, Fortuni M, Caminoa M, Belver T, Quirce S, Caballero T. Anaphylactic reaction to probiotics. Cow's milk and hen's egg allergens in probiotic compounds. *Pediatr Allergy Immunol*. 2012;23(8):778–84. <https://doi.org/10.1111/j.1399-3038.2012.01338.x>.
42. Eda A, Sugai K, Shioya H, Fujitsuka A, Ito S, Iwata T, et al. Acute allergic reaction due to milk proteins contaminating lactose added to corticosteroid for injection. *Allergol Int*. 2009;58(1):137–9. <https://doi.org/10.2332/allergolint.C-07-59>.
43. Porcaro F, Paglietti MG, Diamanti A, Petreschi F, Schiavino A, Negro V, et al. Anaphylactic shock with methylprednisolone sodium succinate in a child with short bowel syndrome and cow's milk allergy. *Ital J Pediatr*. 2017;43(1):104. <https://doi.org/10.1186/s13052-017-0422-4>.
44. Savvatanios S, Giavi S, Stefanaki E, Siragakis G, Manousakis E, Papadopoulos NG. Cow's milk allergy as a cause of anaphylaxis to systemic corticosteroids. *Allergy*. 2011;66:983–5. <https://doi.org/10.1111/j.1398-9995.2011.02566.x>.
45. Levy Y, Segal N, Nahum A, Marcus N, Garty BZ. Hypersensitivity to methylprednisolone sodium succinate in children with milk allergy. *J Allergy Clin Immunol Pract*. 2014;2(4):471–4. <https://doi.org/10.1016/j.jaip.2014.03.002>.
46. Morikawa M, Kanemitsu Y, Tsukamoto H, Morikawa A, Tomioka Y. A case of anaphylaxis in the pediatric patient with milk allergy due to traces of milk protein in the lactose used as an excipient of inavir inhalation. *Alerugi*. 2016;65(3):200–5. <https://doi.org/10.15036/arerugi.65.200>.
47. Santoro A, Andreozzi L, Ricci G, Mastroianni C, Caffarelli C. Allergic reactions to cow's milk proteins in medications in childhood. *Acta Biomed*. 2019;90(3-S):91–93. <https://doi.org/10.23750/abm.v90i3-S.8169>.
48. Nowak-Węgrzyn A, Shapiro GG, Beyer K, Bardina L, Sampson HA. Contamination of dry powder inhalers for asthma with milk proteins containing lactose. *J Allergy Clin Immunol*. 2004;113(3):558–60. <https://doi.org/10.1016/j.jaci.2003.11.015>.
49. Pichler WJ, Campi P. Allergy to lysozyme/egg white-containing vaginal suppositories. *Ann Allergy*. 1992;69(6):521–5.
50. Tan L, Chong KW, Goh SH. Lysozyme and mucolytics - the hidden allergen. *Singapore Med J*. 2020;61(9):497. <https://doi.org/10.11622/smedj.2020132>.
51. Ledesma Benítez I, Regueras Santos L, Lapeña López de Armentia S. Adverse drug reaction as the form of onset of egg sensitization. *An Pediatr (Barc)*. 2007;66(4):424–5. <https://doi.org/10.1157/13101254>.
52. Pérez-Calderón R, Gonzalo-Garijo MA, Lamilla-Yerga A, Mangas-Santos R, Moreno-Gastón I. Recurrent angioedema due to lysozyme allergy. *J Investig Allergol Clin Immunol*. 2007;17(4):264–6.
53. Artesani MC, Donnanno S, Cavagni G, Calzone L, D'Urbano L. Egg sensitization caused by immediate hypersensitivity reaction to drug-containing lysozyme. *Ann Allergy Asthma Immunol*. 2008;101(1):105. [https://doi.org/10.1016/S1081-1206\(10\)60843-5](https://doi.org/10.1016/S1081-1206(10)60843-5).
54. Des Roches A, Graham F, Begin P, Paradis L, Gold M. Evaluation of Adverse Reactions to Vaccines. *J Allergy Clin Immunol Pract*. 2021;9(10):3584–3597. <https://doi.org/10.1016/j.jaip.2021.08.002>.
- This is a very good review of all potential vaccine allergens and management of adverse events after vaccination.
55. Webb L, Petersen M, Boden S, LaBelle V, Bird JA, Howell D, et al. Single-dose influenza vaccination of patients with egg allergy in a multicenter study. *J Allergy Clin Immunol*. 2011;128(1):218–9. <https://doi.org/10.1016/j.jaci.2011.02.013>.
56. Howe LE, Conlon AS, Greenhawt MJ, Sanders GM. Safe administration of seasonal influenza vaccine to children with egg allergy of all severities. *Ann Allergy Asthma Immunol*. 2011;106(5):446–7. <https://doi.org/10.1016/j.anai.2011.01.024>.
57. Greenhawt MJ, Spergel JM, Rank MA, Green TD, Mansoor D, Sharma H, et al. Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy. *Ann Allergy Asthma Immunol*. 2012;109(6):426–30. <https://doi.org/10.1016/j.anai.2012.09.011>.
58. Gagnon R, Primeau MN, Des Roches A, Lemire C, Kagan R, Carr S, et al. PHAC-CIHR Influenza Research Network. Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. *J Allergy Clin Immunol*. 2010;126(2):317–23. <https://doi.org/10.1016/j.jaci.2010.05.037>.
59. Des Roches A, Paradis L, Gagnon R, Lemire C, Bégin P, Carr S, et al. PCIRN (Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network). Egg-allergic patients can be safely vaccinated against influenza. *J Allergy Clin Immunol*. 2012;130(5):1213–1216.e1. <https://doi.org/10.1016/j.jaci.2012.07.046>.
60. Cancado B, Aranda C, Mallozi M, Weckx L, Sole D. Yellow fever vaccine and egg allergy. *Lancet Infect Dis*. 2019;19(8):812. [https://doi.org/10.1016/S1473-3099\(19\)30355-X](https://doi.org/10.1016/S1473-3099(19)30355-X).
61. Gerhardt CMB, Castro APBM, Pastorino AC, Dorna MB, Nunes-Santos CJ, Aquilante BP, et al. Safety of yellow fever vaccine administration in confirmed egg-allergic patients. *Vaccine*. 2020 29;38(42):6539–6544. <https://doi.org/10.1016/j.vaccine.2020.08.020>.
- This study proposes a safe protocol for administration of YFV in egg allergic patients.
62. Chung CH, Mirakhor B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. *N Engl J Med*. 2008;358(11):1109–17. <https://doi.org/10.1056/NEJMo a074943>.
63. Straesser M, Keshavarz B, Borish L, Khokhar D, Holian A, Charlton NP, et al.  $\alpha$ -Gal on Crotalidae-polyvalent Fab antivenom (CroFab): Investigating the relevance to

immediate hypersensitivity reactions. *J Allergy Clin Immunol Pract.* 2021;9(2):1015–1017.e1. <https://doi.org/10.1016/j.jaip.2020.10.026>.

In this paper, the authors examine the frequency of IHR in patients receiving FabAV and demonstrates by means of in vitro techniques that  $\alpha$ -Gal antigen is present on FabAV.

64. Mullins RJ, James H, Platts-Mills TA, Commins S. Relationship between red meat allergy and sensitization to gelatin and galactose- $\alpha$ -1,3-galactose. *J Allergy Clin Immunol.* 2012;129(5):1334–1342.e1. <https://doi.org/10.1016/j.jaci.2012.02.038>.
  65. Vidal C, Méndez-Brea P, López-Freire S, González-Vidal T. Vaginal capsules: an unsuspected probable source of exposure to  $\alpha$ -Gal. *J Investig Allergol Clin Immunol.* 2016;26(6):388–9. <https://doi.org/10.18176/jiaci.0105>.
  66. Stone CA Jr, Hemler JA, Commins SP, Schuyler AJ, Phillips EJ, Peebles RS Jr, et al. Anaphylaxis after zoster vaccine: implicating alpha-gal allergy as a possible mechanism. *J Allergy Clin Immunol.* 2017;139(5):1710–1713.e2. <https://doi.org/10.1016/j.jaci.2016.10.037>.
  67. Stone CA Jr, Commins SP, Choudhary S, Vethody C, Heavrin JL, Wingerter J, et al. Anaphylaxis after vaccination in a pediatric patient: further implicating alpha-gal allergy. *J Allergy Clin Immunol Pract.* 2019;7(1):322–324.e2. <https://doi.org/10.1016/j.jaip.2018.06.005>.
  68. Sakaguchi M, Hori H, Hattori S, Irie S, Imai A, Yanagida M, et al. IgE reactivity to alpha1 and alpha2 chains of bovine type 1 collagen in children with bovine gelatin allergy. *J Allergy Clin Immunol.* 1999;104(3 Pt 1):695–9. [https://doi.org/10.1016/s0091-6749\(99\)70344-1](https://doi.org/10.1016/s0091-6749(99)70344-1).
  69. Jiang Y, Yuan IH, Dutille EK, Bailey R, Shaker MS. Preventing iatrogenic gelatin anaphylaxis. *Ann Allergy Asthma Immunol.* 2019;123(4):366–374. <https://doi.org/10.1016/j.ana.2019.07.017>.
- Literature review about sources of iatrogenic gelatin exposure for management of patients with gelatin allergy.
70. Retterer MKC, Workman LJ, Bacon JR, Platts-Mills TAE. Specific IgE to gelatin as a cause of anaphylaxis to zoster vaccine. *J Allergy Clin Immunol.* 2018;141(5):1956–7. <https://doi.org/10.1016/j.jaci.2017.08.047>.
  71. Martínez A, Audicana MT, Longo N, Ibáñez EF, Balza OV, Velasco M, et al. Allergy to galactose-alpha-1,3-galactose: clinical features and the diagnostic value of cetuximab. *J Investig Allergol Clin Immunol.* 2014;24(6):450–2.
  72. Spoerl D, Scherer K, Bircher AJ. Contact urticaria with systemic symptoms due to hexylene glycol in a topical corticosteroid: case report and review of hypersensitivity to glycols. *Dermatology.* 2010;220(3):238–42. <https://doi.org/10.1159/000275703>.
  73. Munk SJ, Heegaard S, Mosbech H, Garvey LH. Two episodes of anaphylaxis following exposure to hydroxypropyl methylcellulose during cataract surgery. *J Cataract Refract Surg.* 2013;39(6):948–51. <https://doi.org/10.1016/j.jcrs.2013.02.034>.
  74. Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. *Clin Exp Allergy.* 2016;46:907–22. <https://doi.org/10.1111/cea.12760>.
  75. Caballero ML, Quirce S. Immediate hypersensitivity reactions caused by drug excipients: a literature review. *J Investig Allergol Clin Immunol.* 2020;30(2):86–100. <https://doi.org/10.18176/jiaci.0476>.
- Useful overview on allergy to pharmaceutical excipients and the IHRs described with medications that contain them.
76. Sellaturay P, Nasser S, Ewan P. Polyethylene glycol induced systemic allergic reactions (anaphylaxis). *J Allergy Clin Immunol Pract.* 2021;9:670–5. <https://doi.org/10.1016/j.jaip.2020.09.029>. In this report, the authors proposed an useful algorithm to safely investigate suspected PEG allergy.
  77. Yamasuji Y, Higasi Y, Sakanoue M, Katsue H, Kawai K, Arai N, et al. A case of anaphylaxis caused by polyethylene glycol analogues. *Contact Dermatitis.* 2013;68:181–91. <https://doi.org/10.1111/cod.12084>.
  78. Wenade E, Kroigaard M, Mosbech H, Garvey LH. Polyethylene glycols (PEG) and related structures: overlooked allergens in the perioperative setting. *A A Case Rep.* 2015;4(5):61–4. <https://doi.org/10.1213/XAA.0000000000000126>.
  79. Badiu I, Guida G, Heffler E, Rolla G. Multiple drug allergy due to hypersensitivity to polyethylene glycols of various molecular weights. *J Investig Clin Immunol.* 2015;25(5):365–84.
  80. Bruusgaard-Mouritsen MA, Jensen BM, Poulsen LK, Johansen JD, Garvey LH. Optimizing investigation of suspected allergy to polyethylene glycols. *J Allergy Clin Immunol.* 2022;149(1):168–75. <https://doi.org/10.1016/j.jaci.2021.05.020>.
- The authors propose an investigation algorithm for patients with strong and weak suspected PEG allergy based on a titrated step wise approach of SPT. They highlight the usefulness of testing PEG 20,000 if results of SPT with lower MW PEGs are negative and clinical suspicion of PEG allergy is strong.
81. Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Akin C, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and International Consensus Approach. *J Allergy Clin Immunol Pract.* 2021; 9(10): 3546–3567. <https://doi.org/10.1016/j.jaip.2021.06.006>.
- Metha-analysis about recommendations regarding SARS-CoV-2 vaccine immediate allergic reactions in which the authors recommend vaccination without previous testing for individuals with out history of a severe allergic reaction to the SARS-CoV-2 vaccine/excipients.
82. Jakubovic BD, Saperia C, Sussman G. Anaphylaxis following a transvaginal ultrasound. *Allergy Asthma Clin Immunol.* 2016;12:3. <https://doi.org/10.1186/s13223-015-0106-9>.
  83. Brusgaard-Mouritsen MA, Johansen JD, Garvey LH. Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients. *Clin Exp Allergy.* 2021;21:463–70. <https://doi.org/10.1111/cea.13822>.
- Study reporting the need for clear product labelling to prevent repeated anaphylactic reactions with severe impact on patients' lives in allergy to PEG patients.
84. Cox F, Khalib K, Conlon N. PEG that reaction: a case series of allergy to polyethylene glycols. *J Clin Pharmacol.* 2021;61(6):832–5. <https://doi.org/10.1002/jcph.1824>.
  85. Pizzimenti S, Heffler E, Gentilcore E, Raie A, Bussolino C, Nebiolo F, et al. Macrogol hypersensitivity reactions during

- cleansing preparation for colon endoscopy. *J Allergy Clin Immunol Pract.* 2014;2(3):353–4. <https://doi.org/10.1016/j.jaip.2014.01.017>.
86. Borderé A, Stockman A, Boone B, Franki AS, Coppens MJ, Lapeere H, et al. A case of anaphylaxis caused by macrogol 3350 after injection of a corticosteroid. *Contact Dermatitis.* 2012;67(6):376–8. <https://doi.org/10.1111/j.1600-0536.2012.02104.x>.
  87. Arruti N, Longo N, Bernedo N, Girao I, Velasco A, Villarreal O. Anaphylactic shock due to allergy to Macrogol 4000 contained in SonoVue. *Case Rep Clin Med.* 6:143–147. <https://doi.org/10.4236/crcm.2017.66014>.
  88. Habran M, Vandebotermert M, Schrijvers R. Polyethylene glycol allergy and immediate-type hypersensitivity reaction to COVID-19 vaccination: case report. *J Investig Allergol Clin Immunol.* 2022;32(3). <https://doi.org/10.18176/jiaci.0740>.
  89. Perino E, Freymond N, Devouassox G, Nicolas JF, Bérard F. Xolair-induced recurrent anaphylaxis through sensitization to the excipient polysorbate. *Ann Allergy Asthma Immunol.* 2018;120(6):664–6. <https://doi.org/10.1016/j.ana.2018.02.018>.
  90. Kato M, Oiso N, Uchida S, Yanagihara S, Sano H, Tohda Y, et al. Biologic-induced urticaria due to polysorbate 20. *J Dermatol.* 2019;46(7):230–2. <https://doi.org/10.1111/1346-8138.14808>.
  91. Palacios MI, Venturini M, Lobera T, González I, del Pozo MD, Blasco A. Anaphylaxis due to the excipient polysorbate 80. *J Investig Clin Immunol.* 2016;26(6):374–402. <https://doi.org/10.18176/jiaci.0109>.
  92. Pantín C, Letellez J, Calzas J, Mohedano E. Indirect identification of hypersensitivity reaction to etoposide mediated by polysorbate 80. *Farm Hosp.* 2018;42(1):27–8. <https://doi.org/10.7399/fh.10882>.
  93. Badiu I, Geuna M, Heffler E, Rolla G. Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80. *BMJ Case Rep.* 2012;8:2012. <https://doi.org/10.1136/bcr.2012.5797>.
  94. Steele RH, Limaye S, Cleland B, Chow J, Suranyi MG. Hypersensitivity reactions to polysorbate contained in recombinant erythropoietin and darbepoietin. *Nephrology.* 2005;10(3):317–20. <https://doi.org/10.1111/j.1440-1797-2005.00389.x>.
  95. Sellaturay P, Nasser S, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. *Clin Exp Allergy.* 2021;51(6):861–3. <https://doi.org/10.1111/cea.13874>.  
The authors demonstrate for the first time that allergy to PEG can cause anaphylaxis to the Pfizer/BioNTech vaccine.
  96. Schmid P, Wüthrich B. Peranaesthetic anaphylactoid shock due to mannitol. *Allergy.* 1992;47(1):61–2. <https://doi.org/10.1111/j.1398-9995.1992.tb02253.x>.
  97. Findlay SR, Kagey-Sobotka A, Lichtenstein LM. In vitro basophil histamine release induced by mannitol in a patient with a mannitol-induced anaphylactoid reaction. *J Allergy Clin Immunol.* 1984;73(5 Pt 1):578–83. [https://doi.org/10.1016/0091-6749\(84\)90514-1](https://doi.org/10.1016/0091-6749(84)90514-1).
  98. Jain SS, Green S, Rose M. Anaphylaxis following intravenous paracetamol: the problem is the solution. *Anaesth Intensive Care.* 2015;43(6):779–81. <https://doi.org/10.1177/0310057X1504300617>.
  99. Calogiuri GF, Muratore L, Nettis E, Casto AM, Di Leo E, Vacca A. Immediate-type hypersensitivity reaction to Mannitol as drug excipient (E421): a case report. *Eur Ann Allergy Clin Immunol.* 2015;47(3):99–102.
  100. Hegde VL, Venkatesh YP. Anaphylaxis to excipient mannitol: evidence for an immunoglobulin E-mediated mechanism. *Clin Exp Allergy.* 2004;34(10):1602–9. <https://doi.org/10.1111/j.1365-2222.2004.02079.x>.
  101. Wheeler BJ, Taylor BJ. Successful management of allergy to the insulin excipient metacresol in a child with type 1 diabetes: a case report. *J Med Case Rep.* 2012;31(6):263. <https://doi.org/10.1186/1752-1947-6-263>.
  102. Carbonell A, Escudero AI, Miralles JC, González A, Navarro C, Cardona P, Jimeno L, Pineda F. Anaphylaxis Due to Poloxamer 238. *J Investig Allergol Clin Immunol.* 2018;28(6):419–20. <https://doi.org/10.18176/jiaci.0298>.
  103. Rönnau AC, Wulferink M, Gleichmann E, Unver E, Ruzicka T, Krutmann J, et al. Anaphylaxis to polyvinylpyrrolidone in an analgesic preparation. *Br J Dermatol.* 2000;143(5):1055–8. <https://doi.org/10.1046/j.1365-2133.2000.03843.x>.
  104. Pedrosa C, Costa H, Oliveira G, Romariz J, Praça F. Anaphylaxis to povidone in a child. *Pediatr Allergy Immunol.* 2005;16(4):361–2. <https://doi.org/10.1111/j.1399-3038.2005.00272.x>.
  105. Gonzalo Garijo MA, Durán Quintana JA, Bobadilla González P, Máiquez AP. Anaphylactic shock following povidone. *Ann Pharmacother.* 1996;30(1):37–40. <https://doi.org/10.1177/106002809603000107>.
  106. Michavila-Gomez AV, Moreno-Palanques MA, Ferrer-Vazquez M, Ferriols-Leisart R, Bartolomé B. Anaphylactic reaction to povidone secondary to drug ingestion in a young child. *Allergol Immunopathol (Madr).* 2012;40(4):259–61. <https://doi.org/10.1016/j.aller.2011.06.005>.
  107. Liccioli G, Mori F, Barni S, Pucci N, Novembre E. Anaphylaxis to Polyvinylpyrrolidone in Eye Drops Administered to an Adolescent. *J Investig Allergol Clin Immunol.* 2018;28(4):263–5. <https://doi.org/10.18176/jiaci.0252>.
  108. Preuss JF, Goddard CE, Clarke RC, Platt PR, Sadleir PH. Anaphylaxis to intravenous paracetamol containing povidone. A case report and narrative review of excipient allergy related to anaesthesia. *Anaesth Intensive Care.* 2020;48(5):404–408. <https://doi.org/10.1177/0310057X20940318>.
  109. Kim R. Anaphylaxis to protamine masquerading as an insulin allergy. *Del Med J.* 1993;65(1):17–23.
  110. Sánchez MB, Paolillo M, Chacón RS, Camejo M. Protamine as a cause of generalised allergic reactions to NPH insulin. *Lancet.* 1982;1(8283):1243. [https://doi.org/10.1016/s0140-6736\(82\)92362-5](https://doi.org/10.1016/s0140-6736(82)92362-5).
  111. Dykewicz MS, Kim HW, Orfan N, Yoo TJ, Lieberman P. Immunologic analysis of anaphylaxis to protamine component in neutral protamine Hagedorn human insulin. *J Allergy Clin Immunol.* 1994;93(1 Pt 1):117–25. [https://doi.org/10.1016/0091-6749\(94\)90240-2](https://doi.org/10.1016/0091-6749(94)90240-2).
  112. Blanco C, Castillo R, Quiralte J, Delgado J, García I, de Pablos P, et al. Anaphylaxis to subcutaneous neutral protamine Hagedorn insulin with simultaneous sensitization to protamine and insulin. *Allergy.* 1996;51(6):421–4.

113. Lukawska J, Mandaliya D, Chan AWE, Foggitt A, Bidder T, Harvey J, et al. Anaphylaxis to trometamol excipient in gadolinium-based contrast agents for clinical imaging. *J Allergy Clin Immunol Pract.* 2019;7(3):1086–7. <https://doi.org/10.1016/j.jaip.2018.08.035>.
114. Cabanillas B, Novak N. Allergy to COVID-19 vaccines: a current update. *Allergol Int.* 2021;70(3):313–318. <https://doi.org/10.1016/j.alit.2021.04.003>.
- Review about the anaphylactic reactions described for COVID-19 vaccines and detailed description of the characteristics of the different excipients and their potential role in systemic allergic reactions.
115. Ben Ammar I, Ksouri H, Trabelsi N, Mellouli F, Ben Mami F, Dakhli S, et al. Generalized allergy due to zinc in insulin treated with zinc-free insulin. *Acta Diabetol.* 2012;49(3):239–41. <https://doi.org/10.1007/s00592-010-0230-4>.
116. Bruni B, Campana M, Gamba S, Grassi G, Blatto A. A generalized allergic reaction due to zinc in insulin preparation. *Diabetes Care.* 1985;8(2):201. <https://doi.org/10.2337/diacare.8.2.201>.
117. Bruni S, Barolo P, Gamba S, Grassi G, Blatto A. Case of generalized allergy due to zinc and protamine in insulin preparation. *Diabetes Care.* 1986;9(5):552. <https://doi.org/10.2337/diacare.9.5.552b>.
118. Gin H, Aubertin J. Generalized allergy due to zinc and protamine in insulin preparation treated with insulin pump. *Diabetes Care.* 1987;10(6):789–90. <https://doi.org/10.2337/diacare.10.6.789>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.